U
VYNT

UBS’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

UBS’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$13K Hold
9
– – ﹤0.01% 8559
2014
Q2 		$16K Sell
9
-4
-31% -$7.61K ﹤0.01% 8376
2014
Q1 		$28K Hold
13
– – ﹤0.01% 7653
2013
Q4 		$27K Buy
13
+12
+1,200% +$25.9K ﹤0.01% 7779
2013
Q3 		$3K Buy
+1
New +$1.71K ﹤0.01% 9803

Other funds holding VYNT

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.45B AUM 5.8% 1-Year Est. Return
SCM
Sterneck Capital Management Kansas City, Missouri $223M AUM 17.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

UBS's VYNT Position: Q3 2014 in Review

UBS held its Vyant Bio, Inc. Common Stock (VYNT) position steady in Q3 2014 at 9 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #8559.

UBS first reported a position in VYNT in Q3 2013 and has held it in 5 quarters since. The position peaked at $28K in Q1 2014. 28 funds tracked by Wall St. Rank hold VYNT as of Q3 2014.

  • UBS held 9 shares of Vyant Bio, Inc. Common Stock worth $13K as of Q3 2014.
  • UBS left its Vyant Bio, Inc. Common Stock share count unchanged in Q3 2014.
  • Vyant Bio, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8559 holding.
  • UBS first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and has held it in 5 quarters since.
  • UBS's Vyant Bio, Inc. Common Stock position peaked at $28K in Q1 2014.
  • 28 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.